109 related articles for article (PubMed ID: 12923776)
1. Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice.
Sanchez JC; Converset V; Nolan A; Schmid G; Wang S; Heller M; Sennitt MV; Hochstrasser DF; Cawthorne MA
Proteomics; 2003 Aug; 3(8):1500-20. PubMed ID: 12923776
[TBL] [Abstract][Full Text] [Related]
2. Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57Bl/6 lep/lep mice.
Sanchez JC; Converset V; Nolan A; Schmid G; Wang S; Heller M; Sennitt MV; Hochstrasser DF; Cawthorne MA
Mol Cell Proteomics; 2002 Jul; 1(7):509-16. PubMed ID: 12239279
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice.
Edvardsson U; Bergström M; Alexandersson M; Bamberg K; Ljung B; Dahllöf B
J Lipid Res; 1999 Jul; 40(7):1177-84. PubMed ID: 10393202
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice.
Cornick CL; Strongitharm BH; Sassano G; Rawlins C; Mayes AE; Joseph AN; O'Dowd J; Stocker C; Wargent E; Cawthorne MA; Brown AL; Arch JR
J Nutr Biochem; 2009 Oct; 20(10):806-15. PubMed ID: 18926687
[TBL] [Abstract][Full Text] [Related]
5. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.
Lu M; Sarruf DA; Talukdar S; Sharma S; Li P; Bandyopadhyay G; Nalbandian S; Fan W; Gayen JR; Mahata SK; Webster NJ; Schwartz MW; Olefsky JM
Nat Med; 2011 May; 17(5):618-22. PubMed ID: 21532596
[TBL] [Abstract][Full Text] [Related]
6. Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
Duan SZ; Usher MG; Foley EL; Milstone DS; Brosius FC; Mortensen RM
Diabetologia; 2010 Jul; 53(7):1493-505. PubMed ID: 20401461
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality.
Minge CE; Bennett BD; Norman RJ; Robker RL
Endocrinology; 2008 May; 149(5):2646-56. PubMed ID: 18276752
[TBL] [Abstract][Full Text] [Related]
8. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
Tsuchida A; Yamauchi T; Takekawa S; Hada Y; Ito Y; Maki T; Kadowaki T
Diabetes; 2005 Dec; 54(12):3358-70. PubMed ID: 16306350
[TBL] [Abstract][Full Text] [Related]
10. Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment.
Takasawa K; Kubota N; Terauchi Y; Kadowaki T
Endocr J; 2008 Aug; 55(4):767-76. PubMed ID: 18506083
[TBL] [Abstract][Full Text] [Related]
11. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.
Albrektsen T; Frederiksen KS; Holmes WE; Boel E; Taylor K; Fleckner J
Diabetes; 2002 Apr; 51(4):1042-51. PubMed ID: 11916924
[TBL] [Abstract][Full Text] [Related]
12. v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fatty rats.
Maier VH; Melvin DR; Lister CA; Chapman H; Gould GW; Murphy GJ
Diabetes; 2000 Apr; 49(4):618-25. PubMed ID: 10871200
[TBL] [Abstract][Full Text] [Related]
13. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes.
Rieusset J; Auwerx J; Vidal H
Biochem Biophys Res Commun; 1999 Nov; 265(1):265-71. PubMed ID: 10548525
[TBL] [Abstract][Full Text] [Related]
14. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Bedoucha M; Atzpodien E; Boelsterli UA
J Hepatol; 2001 Jul; 35(1):17-23. PubMed ID: 11495036
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
Kast-Woelbern HR; Dana SL; Cesario RM; Sun L; de Grandpre LY; Brooks ME; Osburn DL; Reifel-Miller A; Klausing K; Leibowitz MD
J Biol Chem; 2004 Jun; 279(23):23908-15. PubMed ID: 15073165
[TBL] [Abstract][Full Text] [Related]
17. The peroxisome proliferator activated receptor gamma (PPARgamma) ligand rosiglitazone modulates bronchoalveolar lavage levels of leptin, adiponectin, and inflammatory cytokines in lean and obese mice.
Holguin F; Rojas M; Hart CM
Lung; 2007 Dec; 185(6):367-72. PubMed ID: 17909895
[TBL] [Abstract][Full Text] [Related]
18. Dual Outcomes of Rosiglitazone Treatment on Fatty Liver.
Gao M; Ma Y; Alsaggar M; Liu D
AAPS J; 2016 Jul; 18(4):1023-31. PubMed ID: 27125895
[TBL] [Abstract][Full Text] [Related]
19. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
Gavrilova O; Haluzik M; Matsusue K; Cutson JJ; Johnson L; Dietz KR; Nicol CJ; Vinson C; Gonzalez FJ; Reitman ML
J Biol Chem; 2003 Sep; 278(36):34268-76. PubMed ID: 12805374
[TBL] [Abstract][Full Text] [Related]
20. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
